Search

Purpose: To evaluate of retinal morphology and function progress in patients with diabetes type 2 and DME consistent with the level of pathogenetic factor in tear fluid.Methods: The progress of visual acuity, retinal thickness and photosensitivity after ranibizumab intravitreal injection has been assessed.Results: Statistically significant increase in visual acuity, retinal photosensitivity, decrease of retinal thickness and VEGF A level was found in the tear fluid after injection. The correlation of VEGF level in tear fluid with visual acuity after procedure was found to be negative. Conclusion: Ranibizumab intravitreal injection is a pathogenic treatment leading to morphological and functional retinal state improvement.

Purpose: To compare the results of laser treatment and intravitreal ranibizumab injections in patients with DME consistent with the level of VEGF A in tear fluid.Methods: The progress of visual acuity, retinal thickness and light sensivity after laser treatment and ranibizumab intravitreal injection has been assessed.Results: One month after the treatment the main effect of laser was the decrease of retinal thickness, whereas after ranibizumab — the increase of visual acuity. The significant decrease of VEGF A level in tear fluid was found only in ranibizumab group.Conclusion: Laser treatment of DME leads to permanent retinal thickness decrease and insignificant functional improvement in comparison with ranibizumab IV injection, which leads to temporary morphological and functional improvement.